Title:
HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME
Document Type and Number:
WIPO Patent Application WO/2022/145739
Kind Code:
A1
Abstract:
The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody or a CD19xCD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells. In the present invention, it was confirmed that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells prepared based on a humanized antibody specifically binding to CD22 effectively recognized a CD22 antigen to activate CAR-T cells, and that the CD22-CAR-T cells and bispecific CD19xCD22-CAR-T cells effectively killed cells expressing CD22. Furthermore, it was confirmed that the bispecific CD19xCD22-CAR-T cells exhibited excellent antitumor effects in an animal model.
More Like This:
Inventors:
KIM SEUNG KU (KR)
KIM KI TAE (KR)
KIM KI TAE (KR)
Application Number:
PCT/KR2021/017693
Publication Date:
July 07, 2022
Filing Date:
November 29, 2021
Export Citation:
Assignee:
INNOBATION CO LTD (KR)
International Classes:
C07K16/28; A61P35/00; C07K14/705; C07K14/725; C12N15/62
Domestic Patent References:
| WO2020108644A1 | 2020-06-04 |
Foreign References:
| US20180111992A1 | 2018-04-26 | |||
| US20200087396A1 | 2020-03-19 |
Other References:
DAI HANREN, WU ZHIQIANG, JIA HEJIN, TONG CHUAN, GUO YELEI, TI DONGDONG, HAN XIAO, LIU YANG, ZHANG WENYING, WANG CHUNMENG, ZHANG YA: "Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 13, no. 1, 1 December 2020 (2020-12-01), XP055884985, DOI: 10.1186/s13045-020-00856-8
HUANG CHEN, ZHANG HUI‑CHAO, HO JIN‑YUAN, LIU RUI‑XIA, WANG LIN, KUANG NA, ZHENG MEI‑RONG, LIU LI‑HONG, LI JIAN‑QIANG: "Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report", ONCOLOGY LETTERS, SPANDIDOS PUBLICATIONS, GR, vol. 20, no. 21, 1 January 2020 (2020-01-01), GR , XP055948476, ISSN: 1792-1074, DOI: 10.3892/ol.2020.11882
HUANG CHEN, ZHANG HUI‑CHAO, HO JIN‑YUAN, LIU RUI‑XIA, WANG LIN, KUANG NA, ZHENG MEI‑RONG, LIU LI‑HONG, LI JIAN‑QIANG: "Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report", ONCOLOGY LETTERS, SPANDIDOS PUBLICATIONS, GR, vol. 20, no. 21, 1 January 2020 (2020-01-01), GR , XP055948476, ISSN: 1792-1074, DOI: 10.3892/ol.2020.11882
Attorney, Agent or Firm:
PADO IP LAW PLLC (KR)
Download PDF: